No relationship between osteoprotegerin concentrations and endothelial dysfunction in non-obese women with and without polycystic ovary syndrome
- PMID: 25280574
- DOI: 10.1007/s00404-014-3499-7
No relationship between osteoprotegerin concentrations and endothelial dysfunction in non-obese women with and without polycystic ovary syndrome
Abstract
Purpose: To investigate the relationships of osteoprotegerin (OPG) concentrations to brachial artery flow-mediated vasodilation (FMD) and the carotid artery intima media thickness (CIMT) in polycystic ovary syndrome (PCOS).
Methods: Thirty-seven women with PCOS and 41 controls matched for body mass index (BMI) and age were included in study. The serum OPG concentrations, hormonal and metabolic profiles were measured in women with PCOS and in control group. The CIMT and brachial artery FMD were evaluated in both groups.
Results: The mean serum concentrations of all hormones were comparable, except LH, which was higher in women with PCOS. Lipid parameters were similar between groups. There were no differences between groups with respect to fasting glucose, 2-h glucose, fasting insulin, HbA1c and HOMA-IR. The mean osteoprotogerin concentrations were higher in PCOS group (11.39 ± 2.29 vs. 10.22 ± 2.25 pmol/L, P = 0.026). The mean CIMT was higher in PCOS group than control group (0.52 ± 0.058 vs. 0.45 ± 0.059 mm, P < 0.01). The mean brachial artery FMD was lower in PCOS group (0.068 ± 0.022 vs. 0.055 ± 0.029, P = 0.017).
Conclusions: We found high osteoprotogerin concentrations, increased CIMT and decreased FMD, in women with PCOS. However, there was no correlation between osteoprotegerin and cardiovascular risk markers.
Similar articles
-
Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction.Eur J Endocrinol. 2011 Jan;164(1):61-8. doi: 10.1530/EJE-10-0720. Epub 2010 Oct 25. Eur J Endocrinol. 2011. PMID: 20974706
-
Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome.Eur J Obstet Gynecol Reprod Biol. 2015 Jun;189:19-23. doi: 10.1016/j.ejogrb.2015.03.006. Epub 2015 Mar 9. Eur J Obstet Gynecol Reprod Biol. 2015. PMID: 25837320
-
Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome.BJOG. 2006 Nov;113(11):1308-14. doi: 10.1111/j.1471-0528.2006.01090.x. BJOG. 2006. PMID: 17059392
-
Effects of Metformin on CIMT and FMD in PCOS patients: a systematic review and meta-analysis.BMC Womens Health. 2024 Jul 26;24(1):426. doi: 10.1186/s12905-024-03275-w. BMC Womens Health. 2024. PMID: 39061005 Free PMC article.
-
Endothelial dysfunction in endocrine disease.Trends Endocrinol Metab. 2001 Aug;12(6):257-65. doi: 10.1016/s1043-2760(01)00425-8. Trends Endocrinol Metab. 2001. PMID: 11445443 Review.
Cited by
-
Possible Effect of Polycystic Ovary Syndrome (PCOS) on Cardiovascular Disease (CVD): An Update.J Clin Med. 2024 Jan 25;13(3):698. doi: 10.3390/jcm13030698. J Clin Med. 2024. PMID: 38337390 Free PMC article. Review.
-
Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome.touchREV Endocrinol. 2021 Apr;17(1):37-53. doi: 10.17925/EE.2021.17.1.37. Epub 2021 Apr 28. touchREV Endocrinol. 2021. PMID: 35118445 Free PMC article. Review.
-
Serum Osteoprotegerin Levels and the Vascular Reactivity Index in Patients with Hypertension.Medicina (Kaunas). 2023 Oct 9;59(10):1794. doi: 10.3390/medicina59101794. Medicina (Kaunas). 2023. PMID: 37893512 Free PMC article.
-
Endothelial dysfunction in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: current knowledge and novel biomarkers.Front Endocrinol (Lausanne). 2025 Jun 3;16:1581681. doi: 10.3389/fendo.2025.1581681. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40529825 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical